Newsroom | 16686 results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences’ culture, work environment, and le...

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize...

BRANFORD, Conn.--(BUSINESS WIRE)--Dr. Gloria Sheynkman, University of Virginia, Presents Research utilizing Quantum-Si’s Next-Gen Protein Sequencing™ Platform in Nature Webinar on 5/15...

BOSTON--(BUSINESS WIRE)--Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced the appointment of Paul Conrad, Ph.D., MBA, as chief business and financial officer. Dr. Conrad brings more than 30 years of biopharma experience and expertise spanning R&D, strategy and operations, business and corporate development, alliance management, and finance. “We are ex...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at Clinical Trials...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-002, its wholly owned first-in-class, intravenously (IV) administered gene therapy to enter clinical trials for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). This is the first program entering a human clinical trial utilizing an IV-administered, blood brain...

PALO ALTO, Calif.--(BUSINESS WIRE)--Genascence Corporation (“Genascence”), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced positive 12-month safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). Results from the 12-month analysis showed the study me...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with card...

BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder. EN-374 is a first-in-class in vivo hematopoietic stem cell (HSC)-directed therapy for X-CGD, which is caused by mutations in the CYBB gen...